

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/991,480	11/09/2001	Jean Toma	CIBT-P06-120	4573	
21559	7590 02/19/2004		EXAMINER		
CLARK & ELBING LLP 101 FEDERAL STREET			MURPHY, JOSEPH F		
BOSTON, M	<del></del>		ART UNIT	PAPER NUMBER	
,			1646		

DATE MAILED: 02/19/2004



Please find below and/or attached an Office communication concerning this application or proceeding.

		Applicatio	n No.	Applicant(s)					
Office Action Summary		09/991,480	·	TOMA ET AL.					
		Examiner		Art Unit					
		Joseph F N	lurphy	1646					
The MAILING DATE of this communication appears on the cover she t with the correspondence address Period for Reply									
A SHORTENED STATUTORY P THE MAILING DATE OF THIS C:  - Extensions of time may be available under the after SIX (6) MONTHS from the mailing date.  If the period for reply specified above is less.  If NO period for reply is specified above, the.  Failure to reply within the set or extended per Any reply received by the Office later than the earned patent term adjustment. See 37 CFF	OMMUNICATION. The provisions of 37 CFR 1.13 of this communication. Than thirty (30) days, a reply maximum statutory period with fire the mailing the mailing after the mailing	36(a). In no ever within the statution will will apply and will cause the applic	nt, however, may a reply be tin ory minimum of thirty (30) day expire SIX (6) MONTHS from action to become ABANDONE	nely filed s will be considered time the mailing date of this of D (35 U.S.C. § 133).	ly. communication.				
Status			·						
1) Responsive to communicat	1) Responsive to communication(s) filed on 09 November 2001.								
2a) This action is FINAL.	•								
,—									
Disposition of Claims									
4a) Of the above claim(s) _ 5) Claim(s) is/are allow 6) Claim(s) is/are rejec 7) Claim(s) is/are object	Claim(s) 1-63 is/are pending in the application.  4a) Of the above claim(s) is/are withdrawn from consideration.  Claim(s) is/are allowed.  Claim(s) is/are rejected.  Claim(s) is/are objected to.  Claim(s) is/are subject to restriction and/or election requirement.								
Application Papers									
9)☐ The specification is objected to by the Examiner.									
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.									
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).									
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.									
Priority under 35 U.S.C. § 119									
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of: <ol> <li>Certified copies of the priority documents have been received.</li> <li>Certified copies of the priority documents have been received in Application No</li> <li>Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> </ol> </li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>									
Attachment(s)			A) []	/DTO 442\					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date									
3) Information Disclosure Statement(s) (Pi Paper No(s)/Mail Date			5) Notice of Informal P 6) Other:		O-152)				

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-12, 16-28, 39, 46-50 drawn to cellular compositions of multipotent stem cells and a method of preparing stem cell preparations, classified in class 424, subclass 93.7.
- II. Claims 13-15, 29, drawn to cellular compositions of multipotent stem cells comprising a heterologous gene, classified in class 424, subclass 93.2.
- III. Claims 30-38, 40-45, drawn to methods of treatment by transplanting the multipotent stem cells, classified in class 424, subclass 93.1.
- IV. Claims 51-63, drawn to methods of doing business, classified in class 705, subclass 7.

The inventions are distinct, each from the other because of the following reasons:

Inventions I-II are independent and distinct, each from the other, because they are products which possess characteristic differences in structure and function, and each has an independent use, that is distinct for each invention which cannot be exchanged. Here, the cellular composition comprising stem cells of Group I is distinct from the cellular composition of Group II because the cellular composition of Group II comprises an heterologous nucleic acid. Since these products are distinct, they require non-coextensive searches.

Inventions I and II are related as product and process of use to inventions III and IV. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different

Art Unit: 1646

product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the cellular composition can be used in methods of culturing stem cells.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are

Art Unit: 1646

governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

## Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Joseph F. Murphy whose telephone number is 703-305-7245. The examiner can normally be reached on M-F 7:30-5:00.

Application/Control Number: 09/991,480 Page 5

Art Unit: 1646

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached on 703-308-6564. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-308-0294 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Joseph F. Murphy, Ph. D.

Patent Examiner Art Unit 1646

February 12, 2004